Soluble Interleukin-2 Receptor: A Potential Marker for Monitoring Disease Activity in IgG4-Related Disease by A. F. Karim, L. E. M. Eurelings, R. D. Bansie, P. M. van Hagen, J. A. M. van Laar, W. A. Dik

Get full text

Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study by W. H. A. van Poecke, N. E. F. Hooi, T. K. Mossel, M. A. W. Hermans, P. L. A. van Daele, E. M. Bunnik, Z. Brkic, L. K. Sels, A. A. H. J. Thiadens, P. M. van Hagen, J. A. M. van Laar, S. M. Rombach

Get full text